Summary of Study ST002203

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001406. The data can be accessed directly via it's Project DOI: 10.21228/M80421 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002203
Study TitleSingle Cell Spatial Analysis Reveals the Topology of Immunomodulatory Purinergic Signaling in Glioblastoma
Study SummaryAbstract from manuscript Glioblastoma develops an immunosuppressive microenvironment that fosters tumorigenesis and resistance to current therapeutic strategies. Here we use multiplexed tissue imaging and single-cell RNA-sequencing to characterize the composition, spatial organization, and clinical significance of extracellular purinergic signaling in glioblastoma. We show that glioblastoma exhibit strong expression of CD39 and CD73 ectoenzymes, correlating with increased adenosine levels. Microglia are the predominant source of CD39, while CD73 is principally expressed by tumor cells, particularly in tumors with amplification of EGFR and astrocyte-like differentiation. Spatially-resolved single-cell analyses demonstrate strong spatial correlation between tumor CD73 and microglial CD39, and that their spatial proximity is associated with poor clinical outcomes. Together, this data reveals that tumor CD73 expression correlates with tumor genotype, lineage differentiation, and functional states, and that core purine regulatory enzymes expressed by neoplastic and tumor-associated myeloid cells interact to promote a distinctive adenosine-rich signaling niche and immunosuppressive microenvironment potentially amenable to therapeutic targeting.
Institute
Brigham and Women's Hospital
DepartmentDepartment of Neurosurgery
LaboratoryNathalie Y.R. Agar
Last NameStopka
First NameSylwia
Address60 Fenwood Rd
Emailsstopka@bwh.harvard.edu
Phone617-525-9746
Submit Date2022-06-27
Raw Data AvailableYes
Raw Data File Type(s)imzML
Analysis Type DetailMALDI-MS
Release Date2022-07-15
Release Version1
Sylwia Stopka Sylwia Stopka
https://dx.doi.org/10.21228/M80421
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Collection:

Collection ID:CO002282
Collection Summary:As stated in the manuscript Frozen resection tissue from 9 glioblastomas, including 4 cases with high CD73 and 5 cases with low CD73 by IHC, were selected for MALDI MSI.
Sample Type:Brain
  logo